Taking Bylvay

Building a Routine

Working Bylvay into your existing routine makes it easier to remember to take it, but in the first weeks of starting a new medication, sometimes extra reminders can help. Here are some ideas to help you remember:

Keep a checklist on the kitchen counter
Set a reminder on your mobile phone
Keep the capsules in a days-of-the-week pill box so you can easily check to see if they've been taken
Call your Albireo Assist Care Coordinator for help thinking of ideas that work best for you

Bylvay Instructions for Use Videos

See How Bylvay Oral Pellets are Opened and Sprinkled

Watch this brief instructional video for a demonstration on how to open Bylvay Oral Pellets and mix them with a small amount of soft food.

See How Bylvay Oral Pellets are Opened and Mixed with Liquid

Watch this brief instructional video for a demonstration on how to open Bylvay Oral Pellets and mix them with liquid.

Everyday Help with Bylvay

As you or your child starts treatment with Bylvay, it’s important to incorporate your new medication into your daily routine.

Bylvay should be taken once a day in the morning with a meal. Your doctor will prescribe the right dose based on weight.

Bylvay can be swallowed as a capsule or opened and mixed in a small amount of soft food or liquid
- Use 30mL or 2 tablespoons of soft food (apple sauce, oatmeal, banana or carrot puree, chocolate or rice pudding, etc.)
- Use 5mL or one teaspoon of age-appropriate liquid (breast milk, formula, water, etc.) and give through an oral syringe
If mixing with a liquid, be sure to submerge the contents for at least 5 minutes before administering
- Note, the pellets will not dissolve in liquid
- A measuring syringe is included to squirt the exact dose into the patient's mouth
Food or liquid should be at or below room temperature
Bylvay does not need to be refrigerated

Patients taking bile acid binding resins should take Bylvay at least 4 hours before or 4 hours after the bile acid binding resin.

For complete instructions on taking Bylvay, download the Instructions for Use.

Get more information about our support program
for patients taking Bylvay

IMPORTANT SAFETY INFORMATION AND INDICATIONS

IMPORTANT SAFETY INFORMATION

Speak with your healthcare provider if you experience abdominal pain, vomiting, diarrhea, hematoma, decreased weight, or dehydration as these have been reported with the use of Bylvay. Patients should contact their healthcare provider if they experience new onset or worsening of diarrhea
Elevations in liver tests (for example, AST, ALT, TB) have been observed with use of Bylvay. The patient’s healthcare provider will obtain liver tests before starting Bylvay and periodically during treatment with Bylvay. Patients should report to their healthcare provider any symptoms of liver problems (for example, nausea, vomiting, skin or the whites of eyes turn yellow, dark or brown urine, pain on the right side of the abdomen, loss of appetite)
Bylvay may impair absorption of fat-soluble vitamins (FSV), which include vitamins A, D, E and K (vitamin K is assessed by measuring INR). The patient’s healthcare provider will obtain serum levels of vitamins A, D, E, and INR (for vitamin K) at baseline and periodically during treatment to assess for worsening of FSV deficiency
Do not swallow the 200 mcg or 600 mcg capsule(s) containing Oral Pellets whole. These are intended to be opened and the contents mixed into soft food. Take Bylvay in the morning with a meal
For patients taking bile acid binding resins, take Bylvay at least 4 hours before or 4 hours after taking a bile acid binding resin
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Bylvay during pregnancy. For more information, please call 1-855-252-4736

Indications and Usage

Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in:

Patients 12 months of age and older with Alagille syndrome (ALGS)
Patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
Limitation of Use:
Bylvay may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

IMPORTANT SAFETY INFORMATION

Speak with your healthcare provider if you experience abdominal pain, vomiting, diarrhea, hematoma, decreased weight, or dehydration as these have been reported with the use of Bylvay. Patients should contact their healthcare provider if they experience new onset or worsening of diarrhea
Elevations in liver tests (for example, AST, ALT, TB) have been observed with use of Bylvay. The patient’s healthcare provider will obtain liver tests before starting Bylvay and periodically during treatment with Bylvay. Patients should report to their healthcare provider any symptoms of liver problems (for example, nausea, vomiting, skin or the whites of eyes turn yellow, dark or brown urine, pain on the right side of the abdomen, loss of appetite)
Bylvay may impair absorption of fat-soluble vitamins (FSV), which include vitamins A, D, E and K (vitamin K is assessed by measuring INR). The patient’s healthcare provider will obtain serum levels of vitamins A, D, E, and INR (for vitamin K) at baseline and periodically during treatment to assess for worsening of FSV deficiency
Do not swallow the 200 mcg or 600 mcg capsule(s) containing Oral Pellets whole. These are intended to be opened and the contents mixed into soft food. Take Bylvay in the morning with a meal
For patients taking bile acid binding resins, take Bylvay at least 4 hours before or 4 hours after taking a bile acid binding resin
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Bylvay during pregnancy. For more information, please call 1-855-252-4736

Indications and Usage

Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in:

Patients 12 months of age and older with Alagille syndrome (ALGS)
Patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
Limitation of Use:
Bylvay may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein

Please see full Prescribing Information.